Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multi-center Randomized Double-blind Placebo-controlled Efficacy and Dose Ranging Trial of the Drug Product Seroguard, Solution (JSC Pharmasyntez, Russia) Used for the Prevention of Pelvic Adhesions

NCT03660787 is registered in ClinicalTrials.gov with Pharmasyntez as lead sponsor.

NCT NCT03660787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03660787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multi-center Randomized Double-blind Placebo-controlled Efficacy and Dose Ranging Trial of the Drug Product Seroguard, Solution (JSC Pharmasyntez, Russia) Used for the Prevention of Pelvic Adhesions
Lead sponsor
Pharmasyntez
Phase
Phase 2
Overall status
Completed
Start date
May 4, 2017
Completion date
January 23, 2018
Enrollment
114 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

adhesion